Skip to main content
Erschienen in: Herz 1/2020

11.07.2019 | Review articles

Management of neoplastic pericardial disease

verfasst von: J. Zhang, Q. Zhang, X. Chen, N. Zhang

Erschienen in: Herz | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Abstract

At present, there is no accurate and effective method for treating neoplastic pericardial effusion. This study analyzed the current literature on the treatment of neoplastic pericardial effusion to provide advice and guidance for clinical treatment. Surgical treatments include pericardial puncture, extension of catheter drainage, pericardial window, and surgical pericardiotomy. Each surgical procedure has a corresponding indication, and the best treatment is selected according to the patient’s specific conditions. Systemic chemotherapy is effective in lymphoma and small cell lung cancer that are sensitive to chemotherapeutic drugs. Although pericardial injection of drugs is effective for pericardial tamponade and recurrent pericardial effusion, these methods can only temporarily relieve symptoms and cannot prolong the life of patients. In recent years, immunotherapy, especially adoptive immunotherapy, has achieved good results in the treatment of neoplastic pericardial effusion, thus providing a novel treatment option for neoplastic pericardial effusion.
Literatur
1.
Zurück zum Zitat Mukai K, Shinkai T, Tominaga K, Shimosato Y (1988) The incidence of secondary tumors of the heart and pericardium: a 10-year study. Jpn J Clin Oncol 18(3):195–201PubMed Mukai K, Shinkai T, Tominaga K, Shimosato Y (1988) The incidence of secondary tumors of the heart and pericardium: a 10-year study. Jpn J Clin Oncol 18(3):195–201PubMed
2.
Zurück zum Zitat Taguchi S (2018) Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors. Gen Thorac Cardiovasc Surg 66(5):257–262PubMedCrossRef Taguchi S (2018) Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors. Gen Thorac Cardiovasc Surg 66(5):257–262PubMedCrossRef
3.
Zurück zum Zitat Gromadziński L, Przelaskowski P, Januszko-Giergielewicz B et al (2013) Cardiac tamponade as the first symptom of lung cancer. Pneumonol Alergol Pol 81(2):149–153PubMed Gromadziński L, Przelaskowski P, Januszko-Giergielewicz B et al (2013) Cardiac tamponade as the first symptom of lung cancer. Pneumonol Alergol Pol 81(2):149–153PubMed
4.
Zurück zum Zitat Burazor I, Imazio M, Markel G, Adler Y (2013) Malignant pericardial effusion. Cardiology 124(4):224–232PubMedCrossRef Burazor I, Imazio M, Markel G, Adler Y (2013) Malignant pericardial effusion. Cardiology 124(4):224–232PubMedCrossRef
5.
Zurück zum Zitat Virk SA, Chandrakumar D, Villanueva C, Wolfenden H, Liou K, Cao C (2015) Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 101(20):1619–1626PubMedCrossRef Virk SA, Chandrakumar D, Villanueva C, Wolfenden H, Liou K, Cao C (2015) Systematic review of percutaneous interventions for malignant pericardial effusion. Heart 101(20):1619–1626PubMedCrossRef
6.
Zurück zum Zitat Imazio M, Adler Y (2013) Management of pericardial effusion. Eur Heart J 34(16):1186–1197PubMedCrossRef Imazio M, Adler Y (2013) Management of pericardial effusion. Eur Heart J 34(16):1186–1197PubMedCrossRef
7.
Zurück zum Zitat Loukas M, Walters A, Boon JM, Welch TP, Meiring JH, Abrahams PH (2012) Pericardiocentesis: a clinical anatomy review. Clin Anat 25(7):872–881PubMedCrossRef Loukas M, Walters A, Boon JM, Welch TP, Meiring JH, Abrahams PH (2012) Pericardiocentesis: a clinical anatomy review. Clin Anat 25(7):872–881PubMedCrossRef
8.
Zurück zum Zitat Salem K, Mulji A, Lonn E (1999) Echocardiographically guided pericardiocentesis—the gold standard for the management of pericardial effusion and cardiac tamponade. Can J Cardiol 15(11):1251–1255PubMed Salem K, Mulji A, Lonn E (1999) Echocardiographically guided pericardiocentesis—the gold standard for the management of pericardial effusion and cardiac tamponade. Can J Cardiol 15(11):1251–1255PubMed
9.
Zurück zum Zitat Kennedy UM, Mahony NJ (2006) A cadaveric study of complications associated with the subxiphoid and transthoracic approaches to emergency pericardiocentesis. Eur J Emerg Med 13(5):254–259PubMedCrossRef Kennedy UM, Mahony NJ (2006) A cadaveric study of complications associated with the subxiphoid and transthoracic approaches to emergency pericardiocentesis. Eur J Emerg Med 13(5):254–259PubMedCrossRef
10.
Zurück zum Zitat Maggiolini S, De Carlini CC, Imazio M (2018) Evolution of the pericardiocentesis technique. J Cardiovasc Med (hagerstown) 19(6):267–273CrossRef Maggiolini S, De Carlini CC, Imazio M (2018) Evolution of the pericardiocentesis technique. J Cardiovasc Med (hagerstown) 19(6):267–273CrossRef
11.
Zurück zum Zitat Fitch MT, Nicks BA, Pariyadath M, McGinnis HD, Manthey DE (2012) Videos in clinical medicine. Emergency pericardiocentesis. N Engl J Med 366(12):e17PubMedCrossRef Fitch MT, Nicks BA, Pariyadath M, McGinnis HD, Manthey DE (2012) Videos in clinical medicine. Emergency pericardiocentesis. N Engl J Med 366(12):e17PubMedCrossRef
12.
13.
Zurück zum Zitat Spodick DH (1976) The pericardium: structure, function, and disease spectrum. Cardiovasc Clin 7(3):1–10PubMed Spodick DH (1976) The pericardium: structure, function, and disease spectrum. Cardiovasc Clin 7(3):1–10PubMed
14.
Zurück zum Zitat Allen KB, Faber LP, Warren WH, Shaar CJ (1999) Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 67(2):437–440PubMedCrossRef Allen KB, Faber LP, Warren WH, Shaar CJ (1999) Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 67(2):437–440PubMedCrossRef
15.
Zurück zum Zitat Wagner PL, McAleer E, Stillwell E et al (2011) Pericardial effusions in the cancer population: prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc Surg 141(1):34–38PubMedCrossRef Wagner PL, McAleer E, Stillwell E et al (2011) Pericardial effusions in the cancer population: prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc Surg 141(1):34–38PubMedCrossRef
16.
Zurück zum Zitat El HD, Iliescu C, Yusuf SW et al (2015) Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol 66(10):1119–1128CrossRef El HD, Iliescu C, Yusuf SW et al (2015) Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol 66(10):1119–1128CrossRef
17.
Zurück zum Zitat Jong BH, Wei CC, Shyu KG (2016) Improved hyponatremia after pericardial drainage in patients suffering from cardiac tamponade. BMC Cardiovasc Disord 16:135PubMedPubMedCentralCrossRef Jong BH, Wei CC, Shyu KG (2016) Improved hyponatremia after pericardial drainage in patients suffering from cardiac tamponade. BMC Cardiovasc Disord 16:135PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Adler Y, Charron P, Imazio M et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36(42):2921–2964PubMedCrossRef Adler Y, Charron P, Imazio M et al (2015) 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36(42):2921–2964PubMedCrossRef
19.
Zurück zum Zitat Jama GM, Scarci M, Bowden J, Marciniak SJ (2014) Palliative treatment for symptomatic malignant pericardial effusion. Interact Cardiovasc Thorac Surg 19(6):1019–1026PubMedCrossRef Jama GM, Scarci M, Bowden J, Marciniak SJ (2014) Palliative treatment for symptomatic malignant pericardial effusion. Interact Cardiovasc Thorac Surg 19(6):1019–1026PubMedCrossRef
20.
Zurück zum Zitat Hosomi Y, Ohkuma Y, Shibuya M (2008) Treatment of malignant pericardial effusion. Gan To Kagaku Ryoho 35(6):906–909PubMed Hosomi Y, Ohkuma Y, Shibuya M (2008) Treatment of malignant pericardial effusion. Gan To Kagaku Ryoho 35(6):906–909PubMed
21.
Zurück zum Zitat Olsen PS, Sørensen C, Andersen HO (1991) Surgical treatment of large pericardial effusions. Etiology and long-term survival. Eur J Cardiothorac Surg 5(8):430–432PubMedCrossRef Olsen PS, Sørensen C, Andersen HO (1991) Surgical treatment of large pericardial effusions. Etiology and long-term survival. Eur J Cardiothorac Surg 5(8):430–432PubMedCrossRef
22.
Zurück zum Zitat Altman E, Rutsky O, Shturman A, Yampolsky Y, Atar S (2015) Anterior parasternal approach for creation of a pericardial window. Ann R Coll Surg Engl 97(5):375–378PubMedPubMedCentralCrossRef Altman E, Rutsky O, Shturman A, Yampolsky Y, Atar S (2015) Anterior parasternal approach for creation of a pericardial window. Ann R Coll Surg Engl 97(5):375–378PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Schusler R, Meyerson SL (2018) Pericardial disease associated with malignancy. Curr Cardiol Rep 20(10):92PubMedCrossRef Schusler R, Meyerson SL (2018) Pericardial disease associated with malignancy. Curr Cardiol Rep 20(10):92PubMedCrossRef
24.
Zurück zum Zitat Muhammad MI (2011) The pericardial window: is a video-assisted thoracoscopy approach better than a surgical approach. Interact Cardiovasc Thorac Surg 12(2):174–178PubMedCrossRef Muhammad MI (2011) The pericardial window: is a video-assisted thoracoscopy approach better than a surgical approach. Interact Cardiovasc Thorac Surg 12(2):174–178PubMedCrossRef
25.
Zurück zum Zitat Horr SE, Mentias A, Houghtaling PL et al (2017) Comparison of outcomes of pericardiocentesis versus surgical pericardial window in patients requiring drainage of pericardial effusions. Am J Cardiol 120(5):883–890PubMedCrossRef Horr SE, Mentias A, Houghtaling PL et al (2017) Comparison of outcomes of pericardiocentesis versus surgical pericardial window in patients requiring drainage of pericardial effusions. Am J Cardiol 120(5):883–890PubMedCrossRef
26.
Zurück zum Zitat Puri A, Agarwal N, Dwivedi SK, Narain VS (2012) Percutaneous balloon pericardiotomy for the treatment of recurrent malignant pericardial effusion. Indian Heart J 64(1):88–89PubMedPubMedCentralCrossRef Puri A, Agarwal N, Dwivedi SK, Narain VS (2012) Percutaneous balloon pericardiotomy for the treatment of recurrent malignant pericardial effusion. Indian Heart J 64(1):88–89PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Navarro DALF, Córdoba PM, Orejas OM, López FT, Mohandes M, Iñíguez RA (2002) Percutaneous balloon pericardiotomy in patients with recurrent pericardial effusion. Rev Esp Cardiol 55(1):25–28CrossRef Navarro DALF, Córdoba PM, Orejas OM, López FT, Mohandes M, Iñíguez RA (2002) Percutaneous balloon pericardiotomy in patients with recurrent pericardial effusion. Rev Esp Cardiol 55(1):25–28CrossRef
28.
Zurück zum Zitat Bhardwaj R, Gharib W, Gharib W, Warden B, Jain A (2015) Evaluation of safety and feasibility of percutaneous balloon pericardiotomy in hemodynamically significant pericardial effusion (review of 10-years experience in single center). J Interv Cardiol 28(5):409–414PubMedCrossRef Bhardwaj R, Gharib W, Gharib W, Warden B, Jain A (2015) Evaluation of safety and feasibility of percutaneous balloon pericardiotomy in hemodynamically significant pericardial effusion (review of 10-years experience in single center). J Interv Cardiol 28(5):409–414PubMedCrossRef
29.
Zurück zum Zitat Irazusta FJ, Jiménez-Valero S, Gemma D et al (2017) Percutaneous balloon pericardiotomy: treatment of choice in patients with advanced oncological disease and severe pericardial effusion. Cardiovasc Revasc Med 18(5S1):S14–S17PubMedCrossRef Irazusta FJ, Jiménez-Valero S, Gemma D et al (2017) Percutaneous balloon pericardiotomy: treatment of choice in patients with advanced oncological disease and severe pericardial effusion. Cardiovasc Revasc Med 18(5S1):S14–S17PubMedCrossRef
30.
Zurück zum Zitat Kilicaslan B, Susam I, Dursun H, Ekmekci C, Aydin M, Ozdogan O (2013) Percutaneous balloon pericardiotomy using the Inoue balloon for patients with recurrent pericardial tamponade. Cardiovasc J Afr 24(4):e10–2PubMedCrossRef Kilicaslan B, Susam I, Dursun H, Ekmekci C, Aydin M, Ozdogan O (2013) Percutaneous balloon pericardiotomy using the Inoue balloon for patients with recurrent pericardial tamponade. Cardiovasc J Afr 24(4):e10–2PubMedCrossRef
31.
Zurück zum Zitat Ruiz-García J, Jiménez-Valero S, Moreno R et al (2013) Percutaneous balloon pericardiotomy as the initial and definitive treatment for malignant pericardial effusion. Rev Esp Cardiol 66(5):357–363PubMedCrossRef Ruiz-García J, Jiménez-Valero S, Moreno R et al (2013) Percutaneous balloon pericardiotomy as the initial and definitive treatment for malignant pericardial effusion. Rev Esp Cardiol 66(5):357–363PubMedCrossRef
32.
Zurück zum Zitat Osuch JR, Khandekar JD, Fry WA (1985) Emergency subxiphoid pericardial decompression for malignant pericardial effusion. Am Surg 51(6):298–300PubMed Osuch JR, Khandekar JD, Fry WA (1985) Emergency subxiphoid pericardial decompression for malignant pericardial effusion. Am Surg 51(6):298–300PubMed
33.
Zurück zum Zitat Sakanoue I, Hamakawa H, Okubo Y et al (2016) Efficacy and safety of thoracoscopic pericardial window in patients with pericardial effusions: a single-center case series. J Cardiothorac Surg 11(1):92PubMedPubMedCentralCrossRef Sakanoue I, Hamakawa H, Okubo Y et al (2016) Efficacy and safety of thoracoscopic pericardial window in patients with pericardial effusions: a single-center case series. J Cardiothorac Surg 11(1):92PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Han AJ, Slomka T, Mehrotra A, Murillo LC, Alsafwah SF, Khouzam RN (2016) Paradoxical Hemodynamic instability after pericardial window. Echocardiography 33(8):1251–1252PubMedCrossRef Han AJ, Slomka T, Mehrotra A, Murillo LC, Alsafwah SF, Khouzam RN (2016) Paradoxical Hemodynamic instability after pericardial window. Echocardiography 33(8):1251–1252PubMedCrossRef
35.
Zurück zum Zitat Chung J, Ocken L, Wolo E, Herman CR, Goldhammer JE (2018) Acute right ventricular failure after surgical drainage of pericardial tamponade: a case report of pericardial decompression syndrome and review of the literature. J Cardiothorac Vasc Anesth 33(3):768–771PubMedCrossRef Chung J, Ocken L, Wolo E, Herman CR, Goldhammer JE (2018) Acute right ventricular failure after surgical drainage of pericardial tamponade: a case report of pericardial decompression syndrome and review of the literature. J Cardiothorac Vasc Anesth 33(3):768–771PubMedCrossRef
36.
Zurück zum Zitat Kazantzis T, Bibas BJ, Dela-Vega AJ et al (2019) Predictors of hospital discharge in cancer patients with pericardial effusion undergoing surgical pericardial drainage. J Surg Oncol 119(1):143–147PubMedCrossRef Kazantzis T, Bibas BJ, Dela-Vega AJ et al (2019) Predictors of hospital discharge in cancer patients with pericardial effusion undergoing surgical pericardial drainage. J Surg Oncol 119(1):143–147PubMedCrossRef
38.
Zurück zum Zitat Hanafy AF, El-Egaky AM, Mortada SA, Molokhia AM (2009) Development of implants for sustained release of 5‑fluorouracil using low molecular weight biodegradable polymers. Drug Discov Ther 3(6):287–295PubMed Hanafy AF, El-Egaky AM, Mortada SA, Molokhia AM (2009) Development of implants for sustained release of 5‑fluorouracil using low molecular weight biodegradable polymers. Drug Discov Ther 3(6):287–295PubMed
39.
Zurück zum Zitat Lestuzzi C, Lafaras C, Bearz A et al (2009) Malignant pericardial effusion: sclerotherapy or local chemotherapy. Br J Cancer 101(4):734–735 (author reply 736–7)PubMedPubMedCentralCrossRef Lestuzzi C, Lafaras C, Bearz A et al (2009) Malignant pericardial effusion: sclerotherapy or local chemotherapy. Br J Cancer 101(4):734–735 (author reply 736–7)PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Coburn JM, Kaplan DL (2015) Engineering biomaterial-drug conjugates for local and sustained chemotherapeutic delivery. Bioconjug Chem 26(7):1212–1223PubMedPubMedCentralCrossRef Coburn JM, Kaplan DL (2015) Engineering biomaterial-drug conjugates for local and sustained chemotherapeutic delivery. Bioconjug Chem 26(7):1212–1223PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Sahu P, Kashaw SK, Sau S et al (2018) pH responsive 5‑fluorouracil loaded biocompatible nanogels for topical chemotherapy of aggressive melanoma. Colloids Surf B Biointerfaces 174:232–245PubMedPubMedCentralCrossRef Sahu P, Kashaw SK, Sau S et al (2018) pH responsive 5‑fluorouracil loaded biocompatible nanogels for topical chemotherapy of aggressive melanoma. Colloids Surf B Biointerfaces 174:232–245PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Charron P, Adler Y (2015) “Ten Commandments” of 2015 ESC Guidelines for diagnosis and management of pericardial diseases. Eur Heart J 36(42):2874PubMed Charron P, Adler Y (2015) “Ten Commandments” of 2015 ESC Guidelines for diagnosis and management of pericardial diseases. Eur Heart J 36(42):2874PubMed
43.
Zurück zum Zitat Hikosaka Y, Yano M, Otsuka S et al (2015) Post-irradiation constrictive pericarditis following thymoma treatment: a report of two cases. Gen Thorac Cardiovasc Surg 63(7):413–415PubMedCrossRef Hikosaka Y, Yano M, Otsuka S et al (2015) Post-irradiation constrictive pericarditis following thymoma treatment: a report of two cases. Gen Thorac Cardiovasc Surg 63(7):413–415PubMedCrossRef
44.
45.
Zurück zum Zitat Walker CM, Saldaña DA, Gladish GW et al (2013) Cardiac complications of oncologic therapy. Radiographics 33(6):1801–1815PubMedCrossRef Walker CM, Saldaña DA, Gladish GW et al (2013) Cardiac complications of oncologic therapy. Radiographics 33(6):1801–1815PubMedCrossRef
46.
Zurück zum Zitat Memon A, Zawadzki ZA (1981) Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer 5(8):1–30PubMedCrossRef Memon A, Zawadzki ZA (1981) Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer 5(8):1–30PubMedCrossRef
48.
Zurück zum Zitat Wu X, Liu J, Yang L, Wang F (2018) Photothermally controlled drug release system with high dose loading for synergistic chemo-photothermal therapy of multidrug resistance cancer. Colloids Surf B Biointerfaces 175:239–247PubMedCrossRef Wu X, Liu J, Yang L, Wang F (2018) Photothermally controlled drug release system with high dose loading for synergistic chemo-photothermal therapy of multidrug resistance cancer. Colloids Surf B Biointerfaces 175:239–247PubMedCrossRef
49.
Zurück zum Zitat Upadhyay A, Yagnik B, Desai P, Dalvi SV (2018) Microbubble-mediated enhanced delivery of curcumin to cervical cancer cells. ACS Omega 3(10):12824–12831PubMedPubMedCentralCrossRef Upadhyay A, Yagnik B, Desai P, Dalvi SV (2018) Microbubble-mediated enhanced delivery of curcumin to cervical cancer cells. ACS Omega 3(10):12824–12831PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561PubMedCrossRef Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14:561PubMedCrossRef
51.
Zurück zum Zitat Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–723PubMedPubMedCentralCrossRef Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–723PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Hafeez U, Gan HK, Scott AM (2018) Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr Opin Pharmacol 41:114–121PubMedCrossRef Hafeez U, Gan HK, Scott AM (2018) Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr Opin Pharmacol 41:114–121PubMedCrossRef
53.
Zurück zum Zitat Pol J, Buqué A, Aranda F et al (2016) Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 5(2):e1117740PubMedCrossRef Pol J, Buqué A, Aranda F et al (2016) Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 5(2):e1117740PubMedCrossRef
55.
Zurück zum Zitat Gowrishankar K, Birtwistle L, Micklethwaite K (2018) Manipulating the tumor microenvironment by adoptive cell transfer of CAR T‑cells. Mamm Genome 29(11-12):739–756PubMedCrossRef Gowrishankar K, Birtwistle L, Micklethwaite K (2018) Manipulating the tumor microenvironment by adoptive cell transfer of CAR T‑cells. Mamm Genome 29(11-12):739–756PubMedCrossRef
56.
Zurück zum Zitat Marrone KA, Ying W, Naidoo J (2016) Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther 100(3):242–251PubMedCrossRef Marrone KA, Ying W, Naidoo J (2016) Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther 100(3):242–251PubMedCrossRef
57.
Zurück zum Zitat Chinnasamy D, Yu Z, Theoret MR et al (2010) Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 120(11):3953–3968PubMedPubMedCentralCrossRef Chinnasamy D, Yu Z, Theoret MR et al (2010) Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 120(11):3953–3968PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54(8):707–710PubMedPubMedCentralCrossRef Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54(8):707–710PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Vatsa R, Kumar L, Kumar S, Roy KK, Singh N, Meena J (2018) Frontline use of bevacizumab in ovarian cancer: Experience from India. Natl Med J India 31(1):15–18PubMedCrossRef Vatsa R, Kumar L, Kumar S, Roy KK, Singh N, Meena J (2018) Frontline use of bevacizumab in ovarian cancer: Experience from India. Natl Med J India 31(1):15–18PubMedCrossRef
61.
Zurück zum Zitat Chen D, Zhang Y, Shi F et al (2015) Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review. Onco Targets Ther 8:2767–2770PubMedPubMedCentral Chen D, Zhang Y, Shi F et al (2015) Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review. Onco Targets Ther 8:2767–2770PubMedPubMedCentral
62.
Zurück zum Zitat Chen D, Zhang Y, Shi F et al (2016) Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget 7(32):52436–52441PubMedPubMedCentralCrossRef Chen D, Zhang Y, Shi F et al (2016) Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget 7(32):52436–52441PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Del RM, Tsai H, Dasanu CA (2016) Prolonged survival in colon cancer with malignant pericardial effusion and pulmonary lymphangitic carcinomatosis: a case for monoclonal antibodies. Conn Med 80(8):483–485 Del RM, Tsai H, Dasanu CA (2016) Prolonged survival in colon cancer with malignant pericardial effusion and pulmonary lymphangitic carcinomatosis: a case for monoclonal antibodies. Conn Med 80(8):483–485
64.
Zurück zum Zitat Ueda T, Tsubamoto H, Eguchi A, Terada T, Shibahara H (2016) Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma. Gynecol Oncol Rep 16:11–13PubMedPubMedCentralCrossRef Ueda T, Tsubamoto H, Eguchi A, Terada T, Shibahara H (2016) Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma. Gynecol Oncol Rep 16:11–13PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Oida T, Mimatsu K, Kano H et al (2010) Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World J Gastroenterol 16(6):740–744PubMedPubMedCentralCrossRef Oida T, Mimatsu K, Kano H et al (2010) Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World J Gastroenterol 16(6):740–744PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281PubMedPubMedCentralCrossRef Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Brichard VG, Lejeune D (2007) GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61–B71PubMedCrossRef Brichard VG, Lejeune D (2007) GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61–B71PubMedCrossRef
68.
Zurück zum Zitat Engels B, Engelhard VH, Sidney J et al (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23(4):516–526PubMedPubMedCentralCrossRef Engels B, Engelhard VH, Sidney J et al (2013) Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23(4):516–526PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770PubMedPubMedCentralCrossRef Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758–6770PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Toh U, Fujii T, Seki N, Niiya F, Shirouzu K, Yamana H (2006) Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion. Cancer Immunol Immunother 55(10):1219–1227PubMedCrossRef Toh U, Fujii T, Seki N, Niiya F, Shirouzu K, Yamana H (2006) Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion. Cancer Immunol Immunother 55(10):1219–1227PubMedCrossRef
71.
Zurück zum Zitat Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59(9):1325–1334PubMedPubMedCentralCrossRef Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59(9):1325–1334PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Hu J, Hu J, Liu X, Hu C, Li M, Han W (2017) Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: a meta-analysis. Medicine (Baltimore) 96(42):e8310CrossRef Hu J, Hu J, Liu X, Hu C, Li M, Han W (2017) Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: a meta-analysis. Medicine (Baltimore) 96(42):e8310CrossRef
73.
Zurück zum Zitat Zhao X, Ji CY, Liu GQ et al (2015) Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol 8(10):13146–13155PubMedPubMedCentral Zhao X, Ji CY, Liu GQ et al (2015) Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. Int J Clin Exp Pathol 8(10):13146–13155PubMedPubMedCentral
Metadaten
Titel
Management of neoplastic pericardial disease
verfasst von
J. Zhang
Q. Zhang
X. Chen
N. Zhang
Publikationsdatum
11.07.2019
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-019-4833-4

Weitere Artikel der Sonderheft 1/2020

Herz 1/2020 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.